GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dominari Holdings Inc (FRA:BP2A) » Definitions » Cyclically Adjusted PB Ratio

Dominari Holdings (FRA:BP2A) Cyclically Adjusted PB Ratio : 0.00 (As of Jun. 05, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Dominari Holdings Cyclically Adjusted PB Ratio?

As of today (2024-06-05), Dominari Holdings's current share price is €2.02. Dominari Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €411.32. Dominari Holdings's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Dominari Holdings's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Dominari Holdings's highest Cyclically Adjusted PB Ratio was 1.26. The lowest was 0.01. And the median was 0.01.

FRA:BP2A's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.745
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Dominari Holdings's adjusted book value per share data for the three months ended in Mar. 2024 was €7.389. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €411.32 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Dominari Holdings Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Dominari Holdings's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dominari Holdings Cyclically Adjusted PB Ratio Chart

Dominari Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dominari Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.01

Competitive Comparison of Dominari Holdings's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Dominari Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dominari Holdings's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dominari Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Dominari Holdings's Cyclically Adjusted PB Ratio falls into.



Dominari Holdings Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Dominari Holdings's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.02/411.32
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dominari Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Dominari Holdings's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=7.389/131.7762*131.7762
=7.389

Current CPI (Mar. 2024) = 131.7762.

Dominari Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201406 2,257.213 100.560 2,957.920
201409 2,187.566 100.428 2,870.412
201412 2,085.317 99.070 2,773.756
201503 2,198.560 99.621 2,908.198
201506 397.889 100.684 520.762
201509 249.761 100.392 327.842
201512 228.535 99.792 301.781
201603 193.392 100.470 253.651
201606 144.663 101.688 187.467
201609 179.682 101.861 232.452
201612 73.667 101.863 95.300
201703 60.164 102.862 77.076
201706 32.618 103.349 41.590
201709 49.449 104.136 62.574
201712 40.209 104.011 50.943
201803 60.222 105.290 75.371
201806 61.198 106.317 75.853
201809 47.767 106.507 59.100
201812 89.936 105.998 111.808
201903 81.994 107.251 100.744
201906 72.643 108.070 88.578
201909 51.072 108.329 62.126
201912 33.393 108.420 40.587
202003 15.471 108.902 18.721
202006 13.615 108.767 16.495
202009 12.072 109.815 14.486
202012 11.852 109.897 14.212
202103 16.647 111.754 19.629
202106 16.246 114.631 18.676
202109 16.624 115.734 18.928
202112 17.044 117.630 19.094
202203 16.431 121.301 17.850
202206 16.703 125.017 17.606
202209 16.082 125.227 16.923
202212 13.880 125.222 14.607
202303 13.566 127.348 14.038
202306 10.789 128.729 11.044
202309 10.344 129.860 10.497
202312 8.177 129.419 8.326
202403 7.389 131.776 7.389

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dominari Holdings  (FRA:BP2A) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Dominari Holdings Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Dominari Holdings's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dominari Holdings (FRA:BP2A) Business Description

Traded in Other Exchanges
Address
One Rockefeller Plaza, 11th Floor, New York, NY, USA, 10020
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

Dominari Holdings (FRA:BP2A) Headlines

No Headlines